Biogen Pharmachem Seeks Shareholder Vote on 1:6 Bonus Shares, Capital Increase

STOCK-INVESTMENT-IDEAS
Whalesbook Corporate News Logo
AuthorRiya Kapoor|Published at:
Biogen Pharmachem Seeks Shareholder Vote on 1:6 Bonus Shares, Capital Increase
Overview

Biogen Pharmachem Industries is asking shareholders to approve a 1:6 bonus share issue and raise its authorized capital from ₹91 crore to ₹108 crore. Shareholders will vote via electronic postal ballot from March 27 to April 25, 2026. The company is also seeking approval to appoint M/s. Goenka Mehta & Associates as its new statutory auditors.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Biogen Pharmachem Seeks Shareholder Vote on Bonus Issue and Capital Hike

Biogen Pharmachem Industries Limited is asking shareholders to approve a significant corporate reshuffling, including a bonus share issue and an increase in its authorized capital. The company has initiated a postal ballot process for shareholders to vote on these proposals, which also include appointing new statutory auditors.

The company plans to issue one new bonus equity share for every six shares shareholders currently hold. This bonus issuance will be funded by capitalizing ₹17 crore from the company's Share Premium Account. To support this move and future financial flexibility, Biogen Pharmachem intends to raise its authorized share capital from ₹91 crore to ₹108 crore.

Shareholders will also cast their votes on appointing M/s. Goenka Mehta & Associates as the firm's new statutory auditors, marking a change in its financial oversight.

These corporate actions are aimed at rewarding existing investors by increasing their stake without requiring additional capital outlay. The capital increase also signals the company's potential growth plans, pending shareholder approval. Appointing new auditors is a standard governance step to ensure independent financial scrutiny.

Biogen Pharmachem Industries, an Indian company, focuses on manufacturing Active Pharmaceutical Ingredients (APIs) and chemical intermediates. The company previously conducted a 1:1 bonus share issue in 2015.

No specific risks related to this corporate action were identified in the company's filing or preliminary reviews.

Direct comparisons for bonus share issuances and capital hikes are not commonly available, as these are specific corporate financing decisions rather than operational strategies typically benchmarked against peers.

The electronic postal ballot voting period runs from March 27 to April 25, 2026. Shareholders should monitor the results, expected by April 27, 2026. Investors will also be keen to see how the company utilizes its expanded capital base in future financial disclosures.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.